Another Recommendation On Wall Street for AVROBIO (AVRO). This time with a $38.0 Share Target Price

July 16, 2018 - By Mark Babin

Why Has Wedbush Given AVROBIO (AVRO) a $38.0 Price Target

Wedbush analyst has initiated coverage with a “Outperform” rating on AVROBIO (AVRO) today and set a price target of $38.0. The firm’s shares opened today at 29.74.

The stock increased 5.84% or $1.64 during the last trading session, reaching $29.74. About 110,568 shares traded. AVROBIO, Inc. (AVRO) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral gene therapies to treat rare diseases following a single dose. The company has market cap of $711.88 million. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. It currently has negative earnings. The Company’s lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease.

More notable recent AVROBIO, Inc. (NASDAQ:AVRO) news were published by: 247Wallst.com which released: “IPO News This Week: A Record 12 IPOs Coming to Market” on June 24, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” published on June 21, 2018, Seekingalpha.com published: “US IPO Weekly Recap: Biotechs Boom In A 13-Deal Torrent” on June 23, 2018. More interesting news about AVROBIO, Inc. (NASDAQ:AVRO) were released by: Streetinsider.com and their article: “Wells Fargo Starts Avrobio Inc. (AVRO) at Outperform” published on July 16, 2018 as well as Globenewswire.com‘s news article titled: “AVROBIO, Inc. Announces Pricing of Initial Public Offering” with publication date: June 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.